Aptinyx Inc (NASDAQ:APTX) was up 7.9% on Friday following a better than expected earnings announcement. The company traded as high as $4.49 and last traded at $4.36. Approximately 632,878 shares were traded during mid-day trading, an increase of 57% from the average daily volume of 402,550 shares. The stock had previously closed at $4.04.
The company reported ($0.42) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.12. The business had revenue of $1.04 million for the quarter, compared to the consensus estimate of $1.10 million.
Several research firms have commented on APTX. Cantor Fitzgerald reiterated a “buy” rating and set a $40.00 price objective on shares of Aptinyx in a research report on Monday, December 3rd. Leerink Swann lowered their price objective on shares of Aptinyx from $35.00 to $22.00 and set an “outperform” rating for the company in a research report on Thursday, January 17th. JPMorgan Chase & Co. lowered shares of Aptinyx from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $30.00 to $8.00 in a research report on Thursday, January 17th. BMO Capital Markets lowered their price objective on shares of Aptinyx to $18.00 and set an “outperform” rating for the company in a research report on Friday, January 18th. Finally, Zacks Investment Research upgraded shares of Aptinyx from a “hold” rating to a “buy” rating and set a $6.00 price objective for the company in a research report on Monday, January 21st. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Aptinyx currently has a consensus rating of “Buy” and an average price target of $13.20.
Hedge funds have recently bought and sold shares of the stock. Great West Life Assurance Co. Can purchased a new position in Aptinyx in the 4th quarter worth about $40,000. Legal & General Group Plc purchased a new position in Aptinyx during the 3rd quarter valued at about $58,000. Metropolitan Life Insurance Co. NY increased its position in Aptinyx by 356.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,237 shares of the company’s stock valued at $120,000 after purchasing an additional 5,652 shares during the period. Barclays PLC increased its position in Aptinyx by 87.1% during the 4th quarter. Barclays PLC now owns 9,323 shares of the company’s stock valued at $154,000 after purchasing an additional 4,340 shares during the period. Finally, Wells Fargo & Company MN purchased a new position in Aptinyx during the 3rd quarter valued at about $185,000. 63.11% of the stock is currently owned by institutional investors.
Aptinyx Company Profile (NASDAQ:APTX)
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
See Also: Gross Domestic Product (GDP)
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.